Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)

British Journal of Dermatology

Volumn 171, Issue 6, 2014, Pages 1318-1325

  Chalmers, J R ^a   Schmitt, J ^b   Apfelbacher, C ^c   Dohil, M ^d   Eichenfield, L F ^d   Simpson, E L ^e   Singh, J ^f   Spuls, P ^g   Thomas, K S ^a   Admani, S ^d   Aoki, V ^h   Ardeleanu, M ⁱ   Barbarot, S ^j   Berger, T ^k   Bergman, J N ^l   Block, J ^m   Borok, N ^d   Burton, T ^a   Chamlin, S L ⁿ   Deckert, S ^b   Deklotz, C C ^d   Graff, L B ^o   Hanifin, J M ^e   Hebert, A A ^p   Humphreys, R ^q   Katoh, N ^r   Kisa, R M ^s   Margolis, D J ^t   Merhand, S ^u   Minnillo, R ^v   Mizutani, H ^w   Nankervis, H ^a   Ohya, Y ^x   Rodgers, P ^y   Schram, M E ^g   Stalder, J F ^j   Svensson, A ^z   Takaoka, R ^h   Teper, A ^aa   Tom, W L ^d   Von Kobyletzki, L ^ab   Weisshaar, E ^ac   Zelt, S ^ad   Williams, H C ^a   more..

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ REGENERON PHARMACEUTICALS INC   (United States)

^j NANTES UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m National Eczema Association for Science and Education   (United States)

ⁿ CHILDREN'S MEMORIAL HOSPITAL   (United States)

^o LEO PHARMA A S   (Denmark)

^p UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^q NATIONAL ECZEMA SOCIETY   (United Kingdom)

^r KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^s Centre d'Immunologie Pierre Fabre   (France)

^t UNIVERSITY OF PENNSYLVANIA   (United States)

^u French Association of Eczema   (France)

^v Society for Investigative Dermatology   (United States)

^w MIE UNIVERSITY   (Japan)

^x NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^y LEO Pharma Inc   (United States)

^z LUND UNIVERSITY HOSPITAL   (Sweden)

^aa Sanofi Aventis   (United States)

^ab LUND UNIVERSITY   (Sweden)

^ac UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^ad NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONCEPTUAL FRAMEWORK; CONSENSUS; ECZEMA; HARMONISING MEASURE FOR ECZEMA; HUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN EXAMINATION; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; VALIDATION STUDY; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DERMATITIS, ATOPIC; LONG TERM CARE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; HUMANS; LONG-TERM CARE; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84908096132     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13237     Document Type: Article

References (15)

1. Schmitt J, Williams H,; HOME Development Group. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol 2010; 163: 1166-8.
2. Schmitt J, Spuls P, Boers M, et al,. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012; 67: 1111-17.
3. Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, et al,. Scoring the severity of atopic dermatitis: three Item Severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 1999; 79: 356-9.
4. Schmitt J, Langan S, Deckert S, et al,. Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013; 132: 1337-47.
5. Boers M, Brooks P, Strand CV, Tugwell P,. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998; 25: 198-9.
6. Terwee CB, Bot SD, de Boer MR, et al,. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007; 60: 34-42.
7. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
8. Hanifin JM, Thurston M, Omoto M, et al,. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
9. Charman CR, Venn AJ, Williams H,. Measuring atopic eczema severity visually: which variables are most important to patients? Arch Dermatol 2005; 141: 1146-51.
10. Schmitt J, Langan S, Williams HC,; European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007; 120: 1389-98.
11. de Vet HCW, Terwee CB, Mokkink LB, Knol DL,. Measurement in medicine: A practical guide. New York: Cambridge University Press, 2011.
12. Fuhlbrigge A, Peden D, Apter AJ, et al,. Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012; 129 (Suppl. 3): S34-48.
13. Charman CR, Venn AJ, Williams HC,. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-19.
14. Berth-Jones J,. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol 1996; 135 (Suppl. 48): 25-30.
15. Housman TS, Patel MJ, Camacho F, et al,. Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study. Br J Dermatol 2002; 147: 1192-8.